KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Free Cash Flow data on record, last reported at -$9.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 36.91% year-over-year to -$9.0 million; the TTM value through Dec 2025 reached -$53.0 million, down 47.88%, while the annual FY2025 figure was -$53.0 million, 47.88% down from the prior year.
  • Free Cash Flow reached -$9.0 million in Q4 2025 per AQST's latest filing, up from -$12.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $8.8 million in Q1 2023 and bottomed at -$23.5 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$7.0 million, with a median of -$8.2 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: soared 197.63% in 2022, then tumbled 373.02% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$8.6 million in 2021, then skyrocketed by 197.63% to $8.4 million in 2022, then plummeted by 147.23% to -$4.0 million in 2023, then plummeted by 65.71% to -$6.6 million in 2024, then tumbled by 36.91% to -$9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$9.0 million in Q4 2025, -$12.6 million in Q3 2025, and -$7.9 million in Q2 2025.